Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779509 | 1.00 | LMNA (0.66) | LMNAGAAALDH1A1BCAT1POLB | |
| SCHEMBL4972178 | 0.81 | LMNA (0.70) | LMNAGAAALDH1A1BCAT1KMT2A | |
| SCHEMBL4110091 | 0.81 | LMNA (0.70) | LMNAGAAALDH1A1BCAT1KMT2A | |
| SCHEMBL15761364 | 0.79 | GAA (1.00) | LMNAGAAALDH1A1POLBKMT2A | |
| SCHEMBL29751607 | 0.79 | GAA (1.00) | LMNAGAAALDH1A1POLBKMT2A | |
| SCHEMBL3527258 | 0.78 | LMNA (0.71) | LMNAGAAALDH1A1BCAT1POLB | |
| SCHEMBL7673667 | 0.78 | LMNA (0.71) | LMNAGAAALDH1A1BCAT1POLB | |
| SCHEMBL7673670 | 0.78 | LMNA (0.71) | LMNAGAAALDH1A1BCAT1POLB | |
| SCHEMBL29751720 | 0.78 | LMNA (0.71) | LMNAGAAALDH1A1BCAT1POLB | |
| SCHEMBL3527255 | 0.78 | LMNA (0.71) | LMNAGAAALDH1A1BCAT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060293297-A1 | Cyanofluoropyrrolidine derviative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1627870-A1 | CYANOFLUOROPYRROLIDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293297-A1 | Cyanofluoropyrrolidine derviative | DPP4, DPP3, NPY4R | LMNA 4883/4885GAA 3526/4885ALDH1A1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.